Taiho Pharmaceutical Co. Ltd.

A single-arm study cannot provide interpretable results supporting promotional claims for progression-free survival or overall survival, the US Food and Drug Administration said in an advertising and

Taiho Pharmaceuticals said on 17 March that it will spend $400m up front and up to $740m in milestone payments to expand its cancer drug development pipeline through the acquisition of antibody-drug c

Cullinan Therapeutics and Taiho have a significant market opportunity with zipalertinib after successful results in the Phase I/II REZILIENT1 trial among previously treated non-small cell lung cancer

The theory that LAG-3 inhibitors could help improve survival for colorectal cancer patients has suffered another setback with the failure of a late-stage trial evaluating Merck & Co., Inc. 's favezel